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Abstract
The molecular analysis of individual hematopoietic chimerism at a defined time
after allogeneic hematopoietic stem cell transplantation represents an important
non-specific marker of posttransplant course. The monitoring of its dynamic allows
the identification of patients at a high risk of relapse. A variety of methods are used
for the monitoring of cell chimerism. It is necessary to use sensitive molecular
genetic methods for early detection of the autologous hematopoiesis. Quantitative
multiplex real-time polymerase chain reaction (PCR) analysis can serve as a very
sensitive (0.01–0.1%), relatively quick, and inexpensive method to detect <1% of
minor genotype. With an increasing ratio of minor genotype (>1%), it is more
suitable to use short tandem repeats (STRs) for its analysis. Based on the differences
in recipient/donor pair genotypes, at least two suitable informative polymorphisms
located at different chromosomes can be selected. The combination of methods is
appropriate, and the choice of the used method depends on the patient’s actual
chimerism status. The cohort of 207 patients monitored at the Institute of Hema-
tology and Blood Transfusion was divided into three subgroups according to their
chimerism status (complete chimerism (CC), microchimerism, mixed chimerism
(MC)) 3 years after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
A significant difference in the 3-year survival and 3-year relapse rates in all three
subgroups was found.
Keywords: chimerism, hematopoietic stem cell transplantation,
real-time polymerase chain reaction, short tandem repeats
1. Introduction
The term chimerism comes from Greek mythology. A chimera is a creature with
a lion’s head, a goat’s body, and a snake’s tail. In biology, it is a unique state where
cells from genetically different individuals coexist within one body [1].
A chimerism can spontaneously occur in several situations; probably the most
common is the persistence of fetal progenitor cells in maternal blood [2]. On rare
occasions, a chimerism can be developed in the uterus through the fusion of two
genetically different zygotes (so-called tetragametic chimerism) or from a stem
cell transfusion between dissimilar fraternal twins that share a placenta [3].
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The latter possibility is an engraftment of maternal hematopoietic stem cells,
especially in children with severe combined immunodeficiency.
Artificial cell chimerism can arise after transplantation of an organ, tissue, or
hematopoietic stem cells (HSCT). The allogeneic HSCT (allo-HSCT) is one of the
most used curative options for the treatment of hematological malignant and
nonmalignant diseases, and for some diagnoses, it is currently the only available
therapy. The long-term success of allo-HSCT depends on many factors such as an
appropriate condition regimen (which destroys all leukemic cells), the state of
patient in the time of HSCT (active disease vs. disease remission), the donor’s age
(T lymphocytes of younger donors are more willing to activate and destroy leuke-
mic cells), the modification of the graft (T-cell-depleted graft vs. unmanipulated
graft), and engraftment dynamic of HSC (it was proved that early achievement of
full donor chimerism predicts lower relapse risk in acute lymphoblastic leukemia
(ALL) patients) [4].
The analysis of cell chimerism is an integral part of the posttransplant monitor-
ing of patients. In the immediate posttransplant period, this determination enables
the identification of engraftment dynamics or graft failure, and it allows the early
detection of a patient’s increasing hematopoiesis which indicates a disease relapse.
The principle of the examination is based on the fact that each person has a
unique DNA structure that comprises a set of highly variable polymorphisms; most
polymorphisms are found in the noncoding regions of the genome [5, 6]. Thus, a
comparison of the variable DNA polymorphisms of a patient and a donor provides
information about the origin of the cells in almost every case.
2. Methods for the monitoring of cell chimerism
There are a number of molecular methods (e.g., sex-specific markers,
fluorescence in situ hybridization (FISH), cytogenetic methods, erythrocyte
phenotyping) that have been used for some time for the monitoring of cell
chimerism; however, all of these techniques have their own limitations. They are
laborious or time-consuming as well as have low informativity and sensitivity,
(for a review, see [7, 8]).
2.1 History of molecular genetic methods
The first method of DNA analysis to take advantage of sequence polymorphisms
was the method of restriction fragment length polymorphism (RFLP) where geno-
mic DNA is digested with restriction endonucleases (restrictases) [9]. The size of
the generated fragments is individually specific and depends on the various num-
bers of repetitive units in different individuals. All restriction fragments can be
subsequently separated by gel electrophoresis. Southern blotting is used to transfer
DNA from gel to filter membrane. The fragments are then detected by probe
hybridization. For RFLP analyses it is necessary to extract high molecular weight
undegraded genomic DNA.
The revolution in the monitoring cell of chimerism arose with the introduction
of polymerase chain reaction (PCR) [10]. The first historical method based on PCR
is amplified fragment length polymorphism (AFLP) [11]. Genomic DNA is digested
by restriction enzymes, and the adaptors are subsequently ligated to the restriction
fragments followed by selective PCR amplification with primers compatible to the
adaptor’s sequence. The amplicons are then separated by gel electrophoresis.
In laboratory practice, the most common current methods for long-term
monitoring of cell chimerism are summarized in Table 1. They are based on the
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genotyping and quantification of different polymorphisms using PCR which
provides an unlimited number of copies of a specific DNA segment based on
a single copy.
2.2 Types of polymorphism
Length polymorphisms (loci) are repetitive tandem sequences and individual
alleles (gene forms) that differ in the number of repeats of a sequence motif.
These loci are widespread throughout the human genome and show sufficient
variability among individuals in a population. They have become important in
several fields including genetic mapping; linkage analysis; and human identity
testing. These tandemly repeated regions of DNA are typically classified into several
groups depending on the size of the repeat region such as variable number of
tandem repeats (VNTRs) and short tandem repeats (STRs). The other types
of polymorphisms are short insertions and deletions (InDels) or single-nucleotide
polymorphisms (SNPs).
2.2.1 VNTR
VNTR polymorphisms are minisatellite DNAs with a total sequence length of up
to 1000 base pairs and with a repetitive sequence motif of more than 6 base pairs.
The benefit of VNTR analyses by PCR is a high degree of discrimination and
unlimited quantitative determination, but, on the other hand, the disadvantage is
the low sensitivity of the method (ranges from 1 to 5% depending on the analyzed
VNTR locus and the combination of recipient-donor allele pair). The PCR products
VNTR STR InDel SNP
Type of
polymorphisms
Length Length Insertion and
deletion
Point
Sequence motif
size
10–100 bp 2–6 bp 1–10,000 bp 1 bp
Analysis PCR-specific repetitive
sequence and
subsequent to the
fragment separation on
agarose gel by
electrophoresis
PCR-specific
repetitive sequence
and subsequent to the
fragment separation
on polymer by
capillary
electrophoresis
Quantitative
real-time PCR
Quantitative
real-time PCR
Sensitivity 1–5% 0.4–1% 0.01–0.1% 0.01–0.1%
Advantages High informativity,
unlimited quantitative
determination
High informativity,
unlimited
quantitative
determination
Highest
sensitivity, rapid
Highest
sensitivity, rapid
Disadvantages Low sensitivity, time-
consuming
Moderate sensitivity Lower
informative,
lower accuracy
in the majority
of genotype
quantification
Lower
informative,
lower accuracy
in the majority
of genotype
quantification
VNTR, variable number of tandem repeats; STR, short tandem repeats; InDels, short insertions and deletions; SNP,
single-nucleotide polymorphism; PCR, polymerase chain reaction.
Table 1.
Current possibilities of polymorphism analysis.
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(VNTR alleles) are visualized by fragment analysis via agarose gel electrophoresis,
and when the donor’s and the recipient’s genotypes are detected in the sample
together, the level of chimerism is determined densitometrically.
2.2.2 STR
STR polymorphisms are the repetitive sequences of microsatellite DNAs com-
posed of up to one to six base pairs [12]. However, the most common STRs can
reach, in their final range, from 100 to 500 base pairs [13]. The number of STR
repetitive units may vary widely in populations. There are literally hundreds of STR
systems which have been mapped throughout the human genome [14]. These STR
loci are found on almost every chromosome. Since 1997, the National Institute of
Standards and Technology (NIST) has compiled and maintained a Short Tandem
Repeat DNA Internet Database [15] commonly referred to as STRBase. This
STRBase includes used resources and the summary of human STR polymorphisms,
their basic information, chromosomal location, overview of alleles, population
studies, or available commercial kits. Observed alleles and annotated sequences for
each STR locus are described along with a review of STR analysis technologies [16].
STR markers show a high level of polymorphism and consequently provide a sig-
nificant degree of dissimilarity between individuals [17]. At present, they are con-
sidered to be the most informative genetic markers in the characterization of
biological material. STR analysis is a very robust method with a sensitivity of 0.4–
1% of minor genotype. Compared to VNTR, this method uses smaller quantities of
DNA, including degraded DNA. STR polymorphisms may be amplified using a
variety of PCR primers. Nowadays, a lot of multiplex kits are available on the
market for human genotyping. The method is based on selective PCR of DNA
segments with examined polymorphisms. PCR primers are fluorescently labeled.
Separation of the fragments takes place subsequently in the genetic analyzer by
capillary electrophoresis, as the carrier medium is used a polymer. In the genetic
analyzer, fluorophores are excited by a laser ray to label DNA fragments.
Fluorophores absorb laser light and emit light at a longer wavelength. Using an
optical system, the emitted light is detected and recorded on a charge-coupled
device (CCD) chip. STR alleles are visualized by specific software-like peaks. The
area or height of peaks is used for quantification.
2.2.3 InDel and SNP
InDels are biallelic polymorphisms classified among small genetic variations,
measuring from 1 to 10,000 base pairs in length [18, 19].
SNP is the smallest possible change in DNA sequence in individuals of a
given population. SNPs are most often formed by a point mutation mechanism
that is substitution-like, less often by deleting or inserting at a particular DNA
site. The distribution of SNPs in the genome is not homogeneous. More often,
they occur in noncoding regions, on average 1 of 1000 bp in any selected region
of the genome.
SNP and InDel analysis are performed by real-time quantitative polymerase
chain reaction (RQ-PCR) with specific primers designed to contain appropriate
insertions or deletions or point-to-point substitutions. Real-time PCR allows accu-
rate quantification of amplified products by detection of fluorescence released
during the exponential phase of the reaction. This method can use the non-specific
intercalating fluorescent DNA-binding dye SYBR Green that binds all double-
stranded DNA [20]. More often TaqMan technology is used [21], which utilizes a
fluorescent-labeled target-specific probe resulting in an increased specificity and
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sensitivity compared to the SYBR Green method. Additionally, a variety of fluores-
cent dyes are available so that multiplex PCR can be used to simultaneously amplify
and detect many sequences. The TaqMan probe consists of a fluorophore covalently
attached to the 50 end of the oligonucleotide and the quencher at the 30 end. If the
probe is in an intact state, even when the probe is hybridized to the target sequence,
the emitted fluorescence is suppressed by the quencher. Only during the elongation
phase, when the Taq polymerase with its 50 exonuclease activity degrades the
specifically bound TaqMan probe complex and releases the fluorophore from the
quencher, can fluorescence occur and then be measured. The fluorescence intensity
is directly proportional to the amount of PCR product. The calculation of the
relative amount of target DNA in a sample is done by comparing the Ct values (the
threshold cycle, at which the emitted fluorescent signal exceeds the statistical sig-
nificance level). The resulting portion of the gene of interest (GOI) is calculated by
the ΔΔCT method [22]. Data are normalized with the reference (housekeeping)
gene, and the amplification and detection of the GOI and the reference gene can be
analyzed as a singleplex or multiplex reaction. The multiplex RQ-PCR assay is a
quick, sensitive, reproducible, and cost-effective method for an accurate assessment
[23]. Multiplex RQ-PCR in a routine practice enables an increase in throughput and
reliability, with a reduction in pipetting errors. The sensitivity of this method is
about 0.01% of the minor genotype. Due to the influence of the so-called Monte
Carlo effect (a greater degree of random effect on very low percentages), it is
appropriate to define the lowest significant detection limit of the method. On the
other hand, the RQ-PCR is suitable to use for the quantification of up to about 10%
of the minor genotype, since it has a lower accuracy at higher percentages.
3. Standard procedures for the monitoring of cell chimerism at the
Institute of Hematology and Blood Transfusion
3.1 Informativity determination
The informativity determination always precedes the monitoring of cell chime-
rism. Recipient and donor DNAs are tested by a panel of highly polymorphic STRs
and InDels by multiplex kits. VNTRs and SNPs are not used in our laboratory.
Currently, the PowerPlex 16HS System (Promega, Madison, WI, USA) kit is used
routinely for STR analysis; the kit contains 13 basic Combined DNA Index System
(CODIS) core STR loci [24], sex-specific locus amelogenin, and 2 other
pentanucleotide repeat polymorphisms Penta D and Penta E. For the genotyping of
deletion–insertion polymorphisms (DIP), a Mentype DIPscreen (Biotype, Dresden,
DE) kit is used that amplifies 33 DIP loci and amelogenin. A comparison of the
donor’s and the recipient’s DNA profiles allows to select the specific informative
markers suitable for the monitoring of cell chimerism during the posttrans-
plantation course. We choose at least two informative polymorphisms located at
different chromosomes specific for the recipient. It is necessary to take into account
the potential cytogenetic changes that are associated with different types of cancer
(such as genome instability, loss of heterozygosity, and chromosomal changes)
[25, 26]. Only informative recipient alleles by at least n  2 repeats outside stutter
region (preferably by 2–4 longer) are used for calculation. An artifact of PCR, the
so-called DNA stutter, is a result of strand slippage during DNA synthesis, showing
up primarily one repeat before and, less frequently, one repeat after the true allele.
The result of quantification is that such an allele would lead to an incorrect inter-
pretation. It is always appropriate to quantify the minor genotype; therefore, in the
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case of graft rejection or graft failure (the donor’s cells are present in <50%),
we choose two informative polymorphisms specific for donor in the same way as
the recipient.
3.2 Interpretation of chimerism status
Chimerism is a dynamic process, so the proportion of autologous cells after
allo-HSCT can change during monitoring. It is therefore necessary to approach
each patient individually and to select appropriate methods for quantification.
An overview and definition of the chimerism status are given in Table 2. Under
optimal conditions, we can detect only the donor’s genotype after allo-HSCT; thus,
the recipient’s hematopoiesis is completely replaced with the donor’s graft. We
interpret this as a complete chimerism (CC). In our laboratory the CC is detected by
RQ-PCR, and, based on clinical validation, the significant detection limit was
defined as ≤0.035% of the recipient’s genotype (due to Monte Carlo effect as
mentioned in point 2.2.3). The detection of recipient’s genotype of less than 1% is
interpreted as a microchimerism (range from ≥0.036 to <1%), and the presence of
more than or equal 1% is interpreted as mixed chimerism (MC). The percentages of
the individual alleles are then quantified by STR analysis. If we detect only the
recipient’s genotype or the donor’s genotype less than 0.035%, transplant rejection
and a complete recovery of the original hematopoiesis have occurred. Split chime-
rism can be seen in the analysis of cell fractions. This means that MC is detected in a
certain leukocyte line, but in another cell line, it is CC. The analysis of cell sub-
populations makes it possible to distinguish between residual malignant cells and
nonmalignant hematopoiesis. More often, the fraction of monocytes, granulocytes,
natural killer (NK) cells, T lymphocytes, and B lymphocytes is examined. The
analysis of chimerism of T lymphocytes and NK cells can help, especially, as a guide
to additional therapy in order to avoid graft rejection. The analysis of chimerism
in cell fractions is particularly important for patients with a reduced intensity
regimen before allo-HSCT or patients with autoimmune disease.
The interpretation of bone marrow samples is more difficult. Microchimerism is
often detected as a result of the contamination of the primary sample by bone
marrow stromal cells of the recipient. Therefore, microchimerism below 0.5% of
the recipient’s genotype is considered to be insignificant. The proportion of autolo-
gous hematopoiesis in the bone marrow can fluctuate over time, especially in the
early period after allo-HSCT. In making a clinical decision, it is more important to
watch the dynamics of chimerism and take into account the patient’s diagnosis
rather than the individual values of microchimerism or MC.
Chimerism status Definition
Complete chimerism (CC) Detection of donor’s genotype only or ≤0.035% recipient’s genotype
Microchimerism Detection of donor/recipient ratio ≥0.036 to <1%
Mixed chimerism (MC) Detection of donor/recipient ratio ≥1%
Split chimerism Mixed chimerism is detected in a certain leukocyte line, but in
another cell line, it is complete chimerism
Autologous hematopoiesis Detection of recipient’s genotype only or ≤0.035% donor’s genotype
Table 2.
Interpretation of chimerism status.
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3.3 Posttransplant monitoring
The monitoring of cell chimerism consists of analyzing 2–3 selected informative
polymorphisms. The frequency of monitoring after graft transfer is performed
under our standard days (D) +14, +21, and +28 after allo-HSCT in both adult and
pediatric patients. Subsequently, in pediatric patients, the intervals of examination
are every 2–3 weeks up to D + 180, once a month to the first year after allo-HSCT,
later every 2–4 months up to 3 years after allo-HSCT, and every 6–12 months up to
5 years after allo-HSCT according to the dates of outpatient’s controls. In adult
patients, examinations from the second month after allo-HSCT are carried out in
monthly intervals up to 2 years and, throughout the next period, at least every
6 months. The frequency of examinations depends on the patient’s medical condi-
tion, diagnosis, the dynamics of their chimerism status, and especially the physi-
cian’s decision. In cases of increasing microchimerism or MC detection after the
previous period of CC, an intensive investigation scheme is recommended due to
the risk of graft rejection or relapse of the primary disease.
In the first samples after allo-HSCT, the detection of MC can be expected. If the
recipient’s genotype fraction falls below 50%, we can interpret this as the so-called
engraftment of the donor’s cells. The MC gradually decreases until the patient
reaches CC. The median achievement of CC is most often D + 21 or D + 28 after allo-
HSCT and depends on the patient’s diagnosis and many other factors such as the
regimen of allo-HSCT or the quality of the graft.
The choice of method used depends on the patient’s actual chimerism status.
Due to the high sensitivity of the RQ-PCR method, in combination with STR
analysis, it is advisable to use RQ-PCR for the monitoring of patients in cases where
CC, microchimerism, or MC up to 10% has been detected. On the other hand, with
a rising trend of MC, it is better to use only STR analysis for quantification. For
more accurate determination, it is always necessary to analyze the informative
polymorphisms that detect a minority genotype. This means that in cases where the
MC increases over 50% of the recipient’s genotype, it is preferable to select donor-
specific polymorphisms for quantification.
3.4 The importance of microchimerism
The introduction of the RQ-PCR method for the monitoring of cell chimerism as
a part of routine examination has improved significantly the sensitivity of the
assessment. Its high sensitivity of 0.035% allows for a much earlier detection of
relapses than conventional methods (VNTR and STR). The importance of
microchimerism detection was confirmed by us and many other studies [27–30],
and we would like to present our retrospective data below.
3.4.1 Patients and methods
A group of 224 patients, from HLA-identical-related and HLA-identical-
unrelated donors, who underwent allo-HSCT between 2011 and 2015 at the Institute
of Hematology and Blood Transfusion, were enrolled in this study. Patients with
early HSCT-associated mortality (less than 14 days), another allo-HSCT before the
third year, with no RQ-PCR analyses or with a loss of follow-up were excluded. In
total, 207 patients were eligible for analysis of cell chimerism dynamics. The test
group was divided into 3 subgroups according to chimerism status 3 years after allo-
HSCT: patients with CC (137), patients with microchimerism (38), and patients
with MC (32). The patients’ characteristics are listed in Table 3.
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DNA from whole peripheral blood samples was isolated by means of a salting-
out procedure [31] and diluted to a final concentration of 50 ng/μL. The combina-
tion of InDels by RQ-PCR, in conjunction with STR analysis by fragment analysis,
was used to determine the chimerism status. Fragment analysis of the resulting PCR
products was performed on an automated 3500 Series Genetic Analyzer (Thermo
Fisher Scientific, Waltham, MA, USA), and data were processed by GeneMapper v5
software (Thermo Fisher Scientific). Quantification of MC was determined using
the peak areas representing specific alleles. InDel analysis was performed by means
of TaqMan technology. Rotor-Gene machine (Corbett Life Science, Sydney, New
Number %
Patient characteristic 207 100
Age
Median: 53 years (range 20–67 years)
Sex
Male 130 63
Female 77 57
Diagnostic group
AML 91 44.0
CML 9 4.3
MDS 22 9.6
ALL and LBL 20 9.7
Myeloproliferative disease and MDS/MPS 18 8.7
B-cell non-Hodgkin’s lymphoma 10 4..8
CLL, SLL, PLL 17 8.2
Mature T-cell and NK-cell lymphomas 11 5.3
Hodgkin’s lymphoma 2 1.0
Other diseases 7 3.4
Transplant characteristic
Donor
HLA match 207 100
Match family donor 64 31
Match unrelated donor 143 69
Conditioning regimen
Myeloablative 126 61
Nonmyeloablative 81 39
Stem cell source
PBPC 180 87
BM 27 13
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome;
ALL and LBL, acute lymphoblastic leukemia and lymphoblastic lymphoma; MDS/MPS, myelodysplastic/
myeloproliferative neoplasms; CLL, SLL, PLL, chronic lymphoblastic leukemia, small lymphocytic lymphoma,
prolymphocytic leukemia; PBPC, peripheral blood progenitor cells; BM, bone marrow.
Table 3.
Patient characteristics.
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South Wales) and Rotor-Gene 6 software were used for evaluation. The percentage
of microchimerism was calculated by the ΔΔCT method. Data were normalized
with the glyceraldehyde-3-phosphate dehydrogenase as a reference gene.
The impact of chimerism status on the 3-year overall survival of allo-HSCT
patients and 3-year relapse rates was evaluated using GraphPad Prism 7 software
(La Jolla, CA, USA). The logrank (Mantel-Cox) test was used for comparison of
survival curves.
3.4.2 Results
The 3-year overall survival probability (Figure 1) in our cohort was 59%, and a
significant difference was found in all three subgroups: CC vs. MC (p < 0.0001);
CC vs. microchimerism (p < 0.0001); and MC vs. microchimerism (p = 0.0485).
Overall 85 patients died: the main cause of death was a relapse of the primary
disease (24%); in the second it was pneumonia (20%); and in the third it was
multiple organ failure (15%). Infections, acute GvHD, cerebrovascular accident,
other pulmonary complications, and heart attack occurred less frequently. How-
ever, if we take into account the distribution of patients in the three subgroups
according to their chimerism status, the main cause of death in the CC subgroup
was pneumonia (24%), other infections (16%), and multiple organ failure (16%);
the relapse was only 5% (two patients). In these patients, the last available sample
was taken 2–3 months prior to the relapse date. In the microchimerism subgroup,
the main cause of death was relapse (36%), the second most often was multiple
organ failure (18%), and in the third, it was pneumonia (14%). In the MC subgroup,
most patients died of a relapse (38%), followed by pneumonia (19%), and multiple
organ failure (12%).
Overall, the relapse mortality was 67%. In a correlation of 3-year overall relapse
rates (Figure 2), there was a significant difference between all subgroups: CC vs.
MC patients (p < 0.0001), CC vs. microchimerism patients (p = 0.0073), and MC
vs. microchimerism patients (p = 0.0007). Patients with MC relapsed in 72% of
cases, and the subsequent mortality was 87%. The detection of MC, especially in the
early period after allo-HSCT, is thus an important high-risk factor for a relapse of
the disease. In the microchimerism subgroup, patients relapsed in 34% of cases with
a mortality rate of 69%. The patients with microchimerism are considered to be
potentially at risk. In the CC subgroup, patients relapsed in 15% of cases with a
mortality rate of 29%.
Figure 1.
Three-year overall survival probability according to chimerism status.
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4. Discussion
During the last decades, the effect of MC on the occurrence of imminent relapse
has been investigated. At the beginning of the monitoring of cell chimerism by
RFLP, red cell phenotyping, cytogenetic analysis, or VNTR analysis, there was no
correlation found between the presence of MC and a relapse of the primary disease
[32, 33]. Following the advances in methodology and the introduction of more
sensitive methods for the monitoring of cell chimerism, scientists are increasingly
convinced that there is a connection between the presence of MC and the incidence
of relapse [34, 35]. These observations also support findings that studied the corre-
lation of MC, minimal residual disease, and the presence of a relapse [36, 37]. Our
results support this notion since we found a statistical significant difference
between 3-year relapse rates and 3-year survival probability between all three sub-
groups based on their chimerism status. In addition, there were differences in the
main causes of death: patients with MC and microchimerism died most often with a
relapse, whereas CC patients died mostly of pneumonia.
In the group of patients with MC, it is also advisable to consider the issue of
persisting MC (PMC). In the case of PMC, it depends on the diagnoses. In some
diagnoses, PMC is typical and, usually, does not lead to a relapse (e.g., in
nonmalignant diseases). In another diagnosis, PMC could be a problem; for
instance, in MC patients who have a high percent of autologous cells immediately
after the transplantation, it can often lead to a relapse, and the patients are often
retransplanted. In our cohort of MC patients, there were eight patients without
relapse. One of them relapsed shortly after 3 years, six patients died within first year
after allo-HSCT from other causes, and one patient with primary myelofibrosis has
never reached CC, and he is still around 1% of autologous hematopoiesis without
recurrence of the disease 7 years after allo-HSCT.
The introduction of the RQ-PCRmethod for cell chimerism level monitoring as a
part of routine examination has improved significantly the detection of
microchimerism. The early identification of patients at risk is now possible, and,
due to the early therapeutic intervention, we can avoid the progression to a high-
risk category of MC. Thus, early detection of autologous hematopoiesis is essential
for survival. In the case of MC or microchimerism detection, it is necessary to
accurately quantify the proportion of recipient genotype and monitor its dynamics
over time.
Recently, other studies have also begun to focus on the monitoring of cell
chimerism using the latest technologies such as digital PCR [38] or next-generation
Figure 2.
Three-year overall relapse rates according to chimerism status.
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sequencing [39]. The incorporation of these techniques into routine investigations
depends on subsequent validations that will reveal their advantages or
disadvantages.
5. Conclusion
Molecular analysis of hematopoietic chimerism at a defined period after allo-
HSCT represents a valuable non-specific marker of posttransplant course for all
diagnoses. For some diagnoses this is the only available marker for monitoring. The
aim of cell chimerism analysis is to provide a conclusive base for informed, clinical
decision-making. The establishment of an adequate monitoring schedule, as well as
the selection of appropriate markers and interpretation criteria, will improve the
clinical value of this analysis. The use of sensitive methods, like RQ-PCR for the
monitoring of cell chimerism, is important for the early detection of relapse and
allows the early initiation of medical treatment.
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